keyword
Keywords rituximab Plus CHOP Vs CHOP in...

rituximab Plus CHOP Vs CHOP in non Hodgkin lymphoma

https://read.qxmd.com/read/37664664/br-vs-r%C3%A2-minichop-in-unfit-patients-with-b%C3%A2-cell-non%C3%A2-hodgkin-lymphoma-a-randomized-two%C3%A2-center-cohort-study
#1
JOURNAL ARTICLE
Dongdong Zhang, Yong Lin, Youhong Dong, Liling Zhang
The aim of the present study was to compare the efficacy and safety between the bendamustine plus rituximab (BR) regimen and rituximab combined with low-dose doxorubicin, cyclophosphamide, vincristine and prednisone (R-miniCHOP) in the treatment of 'unfit' patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma grade 3B (FL3B). Patients, >70 years of age with DLBCL or FL3B, defined as unfit according to Comprehensive Geriatric Assessment, were included in the present study. All patients received 4-6 cycles of a BR or R-miniCHOP regimen at a three-week interval...
October 2023: Oncology Letters
https://read.qxmd.com/read/37474340/outcomes-of-patients-with-indolent-lymphoma-treated-with-bendamustine-plus-rituximab-compared-to-rituximab-plus-cvp-or-chop-chemoimmunotherapy-in-ontario
#2
JOURNAL ARTICLE
Adam Suleman, Suriya J Aktar, Zharmaine Ante, Ning Liu, Kelvin K W Chan, Matthew C Cheung, Anca Prica
Bendamustine (B) with rituximab (R) has become the preferred regimen for patients with indolent lymphoma in Ontario, Canada, compared to R with cyclophosphamide, vincristine, prednisone (CVP) or cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). We conducted a propensity-matched retrospective cohort population-based study of patients treated with R-CVP/CHOP from 2005 to 2012 and patients treated with BR from 2013 to 2018. The primary outcome was 5-year overall survival (OS), and secondary outcomes included toxicities and healthcare utilization...
July 20, 2023: British Journal of Haematology
https://read.qxmd.com/read/37379264/subclonal-tp53-mutations-are-frequent-and-predict-resistance-to-radioimmunotherapy-in-follicular-lymphoma
#3
RANDOMIZED CONTROLLED TRIAL
W Richard Burack, Hongli Li, Diana Adlowitz, Janice M Spence, Lisa M Rimsza, Mazyar Shadman, Catherine M Spier, Mark S Kaminski, John P Leonard, Michael L Leblanc, Sonali M Smith, Jonathan W Friedberg
Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in <5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a completed clinical trial, Southwest Oncology Group S0016, a phase 3 randomized intergroup trial of CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) chemotherapy plus R-CHOP (rituximab-CHOP) compared with CHOP chemotherapy plus 131-iodine tositumomab (radioimmunotherapy [RIT]-CHOP)...
September 12, 2023: Blood Advances
https://read.qxmd.com/read/35859066/rituximab-plus-cladribine-versus-r-chop-in-frontline-management-of-marginal-zone-lymphoma-in-china-a-propensity-score-matched-multicenter-study
#4
REVIEW
Yawen Wang, Jiadai Xu, Jing Li, Zheng Wei, Miaojie Shi, Rong Tao, Bobin Chen, Yuyang Tian, Wenhao Zhang, Yan Ma, Lihua Sun, Yunhua Hou, Qilin Zhan, Jigang Wang, Hongwei Xue, Peng Liu
Marginal zone lymphoma (MZL) is an uncommon subtype of non-Hodgkin lymphoma (NHL). Combination of rituximab and cladribine (R-2CdA) is a potential option for indolent NHL (iNHL) and mantle cell lymphoma (MCL) patients. The goal of this multicenter retrospective study was to assess the efficacy and safety of R-2CdA in MZL to support consensus-reaching in first-line therapy in advanced-stage patients. We searched electronic medical records databases of eight centers in China. Between November 2014 and December 2019, 183 symptomatic advanced MZL patients (42 treated with R-2CdA and 141 with rituximab plus cyclophosphamide, adriamycin, vincristine, and prednisone [R-CHOP]) were identified...
July 20, 2022: Annals of Hematology
https://read.qxmd.com/read/33101982/diffuse-large-b-cell-non-hodgkin-s-lymphoma-in-gaucher-disease
#5
JOURNAL ARTICLE
Grant Bonesteele, J Jay Gargus, Emily Curtin, Mabel Tang, Barry Rosenbloom, Virginia Kimonis
Gaucher disease type 1 (GD1) is the most common lysosomal storage disease and affects nearly 1 in 40,000 live births. In addition, it is the most common genetic disorder in the Ashkenazi Jewish population with phenotypic variation presenting in early childhood to asymptomatic nonagenarians. There have been a number of studies showing an increased risk of certain malignancies in patients, especially non- Hodgkin's lymphoma (NHL) and multiple myeloma. We describe a 66-year-old Ashkenazi Jewish male with GD1 who was first started on enzyme replacement therapy (ERT) with imiglucerase for GD1 at age 57 years, followed a year later by the diagnosis of diffuse large b-cell non-Hodgkin's lymphoma (DLBCL)...
December 2020: Molecular Genetics and Metabolism Reports
https://read.qxmd.com/read/32200522/cost-effectiveness-analyses-costs-and-resource-use-and-health-related-quality-of-life-in-patients-with-follicular-or-marginal-zone-lymphoma-systematic-reviews
#6
REVIEW
Neerav Monga, Jamie Garside, Binu Gurung, Joan Quigley, Peter O'Donovan, Christoph Tapprich, Loretta Nastoupil, Catherine Thieblemont, Christina Loefgren
BACKGROUND: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are types of indolent non-Hodgkin lymphoma (NHL) that develop in the B lymphocytes (also known as B cells). OBJECTIVE: The aim of this study was to conduct a comprehensive review of studies relating to cost effectiveness, costs and resource use, and health-related quality of life (HRQoL) in patients with FL or MZL. METHODS: Three separate systematic reviews were conducted to identify all published evidence on cost effectiveness, costs and resource use, and HRQoL between 2007 and March 2017 using the MEDLINE® , MEDLINE in-process, E-pubs ahead of print (Ovid SP® ), Embase (Ovid SP® ), NHS EED, and EconLit databases...
December 2020: PharmacoEconomics Open
https://read.qxmd.com/read/31868632/four-versus-six-cycles-of-chop-chemotherapy-in-combination-with-six-applications-of-rituximab-in-patients-with-aggressive-b-cell-lymphoma-with-favourable-prognosis-flyer-a-randomised-phase-3-non-inferiority-trial
#7
RANDOMIZED CONTROLLED TRIAL
Viola Poeschel, Gerhard Held, Marita Ziepert, Mathias Witzens-Harig, Harald Holte, Lorenz Thurner, Peter Borchmann, Andreas Viardot, Martin Soekler, Ulrich Keller, Christian Schmidt, Lorenz Truemper, Rolf Mahlberg, Reinhard Marks, Heinz-Gert Hoeffkes, Bernd Metzner, Judith Dierlamm, Norbert Frickhofen, Mathias Haenel, Andreas Neubauer, Michael Kneba, Francesco Merli, Alessandra Tucci, Peter de Nully Brown, Massimo Federico, Eva Lengfelder, Alice di Rocco, Ralf Trappe, Andreas Rosenwald, Christian Berdel, Martin Maisenhoelder, Ofer Shpilberg, Josif Amam, Konstantinos Christofyllakis, Frank Hartmann, Niels Murawski, Stephan Stilgenbauer, Maike Nickelsen, Gerald Wulf, Bertram Glass, Norbert Schmitz, Bettina Altmann, Markus Loeffler, Michael Pfreundschuh
BACKGROUND: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis. METHODS: This two-arm, open-label, international, multicentre, prospective, randomised phase 3 non-inferiority trial was done at 138 clinical sites in Denmark, Israel, Italy, Norway, and Germany...
December 21, 2019: Lancet
https://read.qxmd.com/read/29295612/the-effect-of-the-dexamethasone-cytarabine-and-cisplatin-dhap-regimen-on-stem-cell-mobilization-and-transplant-outcomes-of-patients-with-non-hodgkin-s-lymphoma-who-are-candidates-for-up-front-autologous-stem-cell-transplantation
#8
MULTICENTER STUDY
So Yeon Jeon, Ho-Young Yhim, Hee Sun Kim, Jeong-A Kim, Deok-Hwan Yang, Jae-Yong Kwak
BACKGROUND/AIMS: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin's lymphoma (NHL) is limited. METHODS: Consecutive patients with aggressive NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab-CHOP who underwent chemomobilization using HDC or DHAP plus granulocyte-colony stimulating factor (G-CSF) for up-front ASCT were enrolled from three institutions between 2004 and 2014...
November 2018: Korean Journal of Internal Medicine
https://read.qxmd.com/read/28476440/efficacy-and-safety-of-subcutaneous-rituximab-versus-intravenous-rituximab-for-first-line-treatment-of-follicular-lymphoma-sabrina-a-randomised-open-label-phase-3-trial
#9
RANDOMIZED CONTROLLED TRIAL
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov, Mark Dixon, Michael Brewster, Martin Barrett, David MacDonald
BACKGROUND: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care. We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety data. METHODS: SABRINA is a two-stage, randomised, open-label phase 3 study at 113 centres in 30 countries...
June 2017: Lancet Haematology
https://read.qxmd.com/read/27103007/bendamustine-plus-rituximab-versus-r-chop-as-first-line-treatment-for-patients-with-indolent-non-hodgkin-s-lymphoma-evidence-from-a-multicenter-retrospective-study
#10
MULTICENTER STUDY
Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, Ines Wasle, Francesco Zaja, Renato Zambello, Andrea Visentin, Endri Mauro, Simone Ferrero, Paola Ghione, Vincenzo Pitini, Salvatore Cuzzocrea, Michael Mian
The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still highly debated. Recently, the StiL and the BRIGHT trials showed that the combination of rituximab and bendamustine (R-B) is non-inferior to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a better toxicity profile. Utilizing a retrospective analysis, we compared the efficacy and safety of both regimens in clinical practice. From November 1995 to January 2014, 263 LG-NHL patients treated with either R-B or R-CHOP were retrospectively assessed in seven European cancer centers...
June 2016: Annals of Hematology
https://read.qxmd.com/read/24604961/histopathological-pattern-of-lymphomas-and-clinical-presentation-and-outcomes-of-diffuse-large-b-cell-lymphoma-a-multicenter-registry-based-study-from-india
#11
JOURNAL ARTICLE
Ramesh B V Nimmagadda, Raghunadharao Digumarti, Reena Nair, Dinesh Bhurani, Vinod Raina, Shyam Aggarwal, Shekhar Patil, Pabitra K Gogoi, Subramanian Sundaram, Chanchal Goswami, Shashikant Apte, Srinivas Chakravarthy, Anand Pathak
CONTEXT: The distribution of various subtypes of lymphomas in India is different from other parts of the world. There is scarce multicentric data on the pattern and outcomes of lymphomas in India. AIMS: The aim of this study is to evaluate the histopathological and the clinical pattern and treatment outcomes of lymphomas in India based on the retrospective data collected from a multicenter registry. MATERIALS AND METHODS: Retrospective data was collected at 13 public and private hospitals in India for patients diagnosed with lymphoma between January 2005 and December 2009...
October 2013: Indian Journal of Medical and Paediatric Oncology
https://read.qxmd.com/read/24591201/randomized-trial-of-bendamustine-rituximab-or-r-chop-r-cvp-in-first-line-treatment-of-indolent-nhl-or-mcl-the-bright-study
#12
RANDOMIZED CONTROLLED TRIAL
Ian W Flinn, Richard van der Jagt, Brad S Kahl, Peter Wood, Tim E Hawkins, David Macdonald, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Regina Clementi, Doreen M Hallman, Mihaela Munteanu, Ling Chen, John M Burke
This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab (BR) vs a standard rituximab-chemotherapy regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or rituximab plus cyclophosphamide, vincristine, and prednisone [R-CVP]) for treatment-naive patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma. Investigators preassigned the standard treatment regimen they considered most appropriate for each patient; patients were randomized to receive BR (n = 224) or standard therapy (R-CHOP/R-CVP, n = 223) for 6 cycles; 2 additional cycles were permitted at investigator discretion...
May 8, 2014: Blood
https://read.qxmd.com/read/24171516/autologous-transplantation-as-consolidation-for-aggressive-non-hodgkin-s-lymphoma
#13
RANDOMIZED CONTROLLED TRIAL
Patrick J Stiff, Joseph M Unger, James R Cook, Louis S Constine, Stephen Couban, Douglas A Stewart, Thomas C Shea, Pierluigi Porcu, Jane N Winter, Brad S Kahl, Thomas P Miller, Raymond R Tubbs, Deborah Marcellus, Jonathan W Friedberg, Kevin P Barton, Glenn M Mills, Michael LeBlanc, Lisa M Rimsza, Stephen J Forman, Richard I Fisher
BACKGROUND: The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the International Prognostic Index remains controversial and is untested in the rituximab era. METHODS: We treated 397 patients who had disease with an age-adjusted classification of high risk or high-intermediate risk with five cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP plus rituximab...
October 31, 2013: New England Journal of Medicine
https://read.qxmd.com/read/24028444/primary-vs-secondary-prophylaxis-with-pegfilgrastim-for-the-reduction-of-febrile-neutropenia-risk-in-patients-receiving-chemotherapy-for-non-hodgkin-s-lymphoma-cost-effectiveness-analyses
#14
JOURNAL ARTICLE
Gregory Hill, Richard Barron, Kelly Fust, Michelle E Skornicki, Douglas C A Taylor, Milton C Weinstein, Gary H Lyman
OBJECTIVE: Evaluate the cost-effectiveness of primary vs secondary prophylaxis (PP vs SP) with pegfilgrastim to reduce the risk of febrile neutropenia (FN) in Non-Hodgkin's Lymphoma (NHL) patients receiving myelosuppressive chemotherapy from a US payer perspective. METHODS: A Markov model was used to compare PP vs SP with pegfilgrastim in a cohort of patients receiving six cycles of cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) or CHOP plus rituximab (CHOP-R) chemotherapy...
January 2014: Journal of Medical Economics
https://read.qxmd.com/read/23615461/rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-in-patients-with-newly-diagnosed-diffuse-large-b-cell-non-hodgkin-lymphoma-a-phase-3-comparison-of-dose-intensification-with-14-day-versus-21-day-cycles
#15
RANDOMIZED CONTROLLED TRIAL
David Cunningham, Eliza A Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M Ardeshna, John A Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David Linch
BACKGROUND: Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. We investigated whether this survival benefit from dose intensification persists in the presence of rituximab (R-CHOP) in all age groups. METHODS: Patients (aged ≥18 years) with previously untreated bulky stage IA to stage IV diffuse large B-cell lymphoma in 119 centres in the UK were randomly assigned centrally in a one-to-one ratio, using minimisation, to receive six cycles of R-CHOP every 14 days plus two cycles of rituximab (R-CHOP-14) or eight cycles of R-CHOP every 21 days (R-CHOP-21)...
May 25, 2013: Lancet
https://read.qxmd.com/read/23053189/point-prevalence-of-pneumocystis-pneumonia-in-patients-with-non-hodgkin-lymphoma-according-to-the-number-of-cycles-of-r-chop-chemotherapy
#16
JOURNAL ARTICLE
Tark Kim, Sang-Ho Choi, Sung-Han Kim, Jin-Yong Jeong, Jun Hee Woo, Yang Soo Kim, Heungsup Sung, Mi-Na Kim, Dok Hyun Yoon, Cheolwon Suh, Sang-Oh Lee
R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. We estimated the point prevalence of Pneumocystis pneumonia in non-Hodgkin lymphoma patients according to the number of R-CHOP cycles and investigated whether cytoreduction by chemotherapy is associated with Pneumocystis pneumonia development. We retrospectively established a cohort of patients who received R-CHOP for non-Hodgkin lymphoma in our institution...
January 2013: Annals of Hematology
https://read.qxmd.com/read/22752146/treatment-option-of-bendamustine-in-combination-with-rituximab-in-elderly-and-frail-patients-with-aggressive-b-non-hodgkin-lymphoma-rational-efficacy-and-tolerance
#17
JOURNAL ARTICLE
Julia Horn, Martina Kleber, Stefanie Hieke, Annette Schmitt-Gräff, Ralph Wäsch, Monika Engelhardt
We analyzed the safety and efficacy of rituximab plus bendamustine (R-B) in elderly and frail patients with aggressive B-non-Hodgkin lymphoma (a-B-NHL). Few reports have as yet reported on R-B in a-B-NHL, albeit its value for indolent lymphoma vs. R-CHOP has impressively been shown. We assessed 20 consecutive patients with a-B-NHL receiving R-B as first-line or relapse treatment after (R)-CHOP in our department. Besides patient- and lymphoma-specific characteristics, comorbidity indices were determined. The median patient age was 72 years (51-86), the median Karnofsky performance status was 55 % (40-90 %), and according to the international prognostic index, 15 had high-intermediate or high-risk disease...
October 2012: Annals of Hematology
https://read.qxmd.com/read/22704490/the-clinical-features-therapeutic-responses-and-prognosis-of-the-patients-with-mantle-cell-lymphoma
#18
JOURNAL ARTICLE
Zhi-Tao Ying, Wen Zheng, Xiao-Pei Wang, Yan Xie, Mei-Feng Tu, Ning-Jing Lin, Ling-Yan Ping, Wei-Ping Liu, Li-Juan Deng, Chen Zhang, Jun Zhu, Yu-Qin Song
Mantle cell lymphoma(MCL), a special type of non-Hodgkin's lymphoma, is incurable through conventional treatment. This study aimed to analyze the clinical features, therapeutic responses, and prognosis of patients with MCL. Clinical data of 30 patients with MCL treated in our hospital between April 2006 and July 2011 were analyzed. Eighteen patients were treated with CHOP plus rituximab (R-CHOP) regimen, 12 underwent conventional chemotherapy. The median age of the 30 patients was 58 years, 23 were men, all patients had Cyclin D1 overexpression, 29 (96...
July 2012: Chinese Journal of Cancer
https://read.qxmd.com/read/22180164/pooled-analysis-of-aids-malignancy-consortium-trials-evaluating-rituximab-plus-chop-or-infusional-epoch-chemotherapy-in-hiv-associated-non-hodgkin-lymphoma
#19
COMPARATIVE STUDY
Stefan K Barta, Jeannette Y Lee, Lawrence D Kaplan, Ariela Noy, Joseph A Sparano
BACKGROUND: Improved outcomes have recently been reported for rituximab (R) plus rituximab plus infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) chemotherapy in patients with human immunodeficiency virus (HIV)-associated, aggressive B-cell, non-Hodgkin lymphoma (NHL). The objective of the current analysis was to assess whether patient selection or other factors contributed to this improvement and to identify patients who are at the greatest risk for lethal toxicity...
August 15, 2012: Cancer
https://read.qxmd.com/read/16923561/rituximab-chop-eshap-vs-chop-eshap-high-dose-therapy-vs-conventional-chop-chemotherapy-in-high-intermediate-and-high-risk-aggressive-non-hodgkin-s-lymphoma
#20
JOURNAL ARTICLE
Tanin Intragumtornchai, Udomsak Bunworasate, Thanyaphong Na Nakorn, Ponlapat Rojnuckarin
With currently available combination chemotherapy regimens, the outcome of the patients newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high' and 'high-intermediate' risk groups according to the international prognostic index (IPI) is still unsatisfactory and a more innovative therapy is urgently required to improve the survival of the patients. The purpose of this study was to compare the efficacy of rituximab given in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and ESHAP (etoposide, methylprednisolone, high-dose Ara-C, cisplatin) vs CHOP-ESHAP and upfront high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) vs standard CHOP in patients aged < or = 65 years old newly diagnosed with 'high' and 'high-intermediate' risk aggressive lymphoma enrolled onto two consecutive treatment trials at the institute...
July 2006: Leukemia & Lymphoma
keyword
keyword
110998
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.